Health Canada Approves Neffy: The First Needle-Free Epinephrine Nasal Spray for Anaphylaxis
For millions of Canadians living with severe allergies, the fear of anaphylaxis is often compounded by the stress of using an epinephrine auto-injector. The requirement for a needle can lead to hesitation or delay during a life-threatening emergency. That is changing this year. Health Canada has officially approved Neffy, the first needle-free epinephrine treatment designed to treat severe allergic reactions via a nasal spray.
- What it is: A 2 mg epinephrine nasal spray for the emergency treatment of anaphylaxis.
- Who it’s for: Adults and pediatric patients weighing at least 30 kg (approximately 66 lbs).
- Availability: Expected to be on the Canadian market as soon as summer 2026.
- Key Advantage: Eliminates the necessitate for needles, potentially reducing treatment delays caused by needle phobia.
A Fresh Approach to Emergency Allergy Treatment
Until now, epinephrine auto-injectors (AAIs), such as the well-known EpiPen, were the only emergency treatment options available for anaphylaxis. These devices deliver a dose of epinephrine directly into the muscle. While effective, the “needle” aspect of AAIs can be a significant barrier.
Dr. Mariam Hanna, an adjunct clinical professor of pediatrics at McMaster University, notes that some patients and parents feel reluctant to utilize auto-injectors. In a life-threatening reaction, any delay in administering epinephrine can negatively impact patient outcomes. Neffy’s non-needle delivery system aims to remove this psychological barrier, allowing caregivers and patients to act more quickly and confidently.
Clinical Specifications and Use Cases
Developed by ALK, Neffy is approved for the emergency treatment of allergic reactions caused by:
- Insect stings or bites
- Foods
- Medicinal products
- Other allergens
- Idiopathic or exercise-induced anaphylaxis
Patient Eligibility
The 2 mg dose is approved for use in adults and children who weigh 30 kilograms (66 lbs) or more.
Why Neffy is a “Game Changer”
Beyond the lack of a needle, Neffy offers several practical advantages over traditional auto-injectors that make it more resilient for daily carry:
1. Temperature Stability
Unlike many auto-injectors, Neffy can withstand temperature excursions up to 50°C. This makes it significantly more durable in varying climates, such as a hot car or during travel.
2. Extended Shelf Life
The nasal spray features a 30-month shelf life from the time of manufacture, providing a longer window of usability than some existing alternatives.
3. Portability
The device is designed to fit easily into a pocket, ensuring that the medication is readily accessible the moment a reaction begins.
Safety and Evidence
The Health Canada approval followed a review of data from a development program involving more than 700 participants. According to ALK, no serious side effects were reported during these clinical studies. With an estimated 2.5 million people in Canada affected by severe allergies, this approval addresses a critical gap in emergency care.
Frequently Asked Questions
Will Neffy replace the EpiPen?
Neffy provides a new alternative for those who uncover auto-injectors stressful or challenging to deploy. It expands the options available to patients, but the choice of treatment will likely depend on individual patient needs and physician guidance.
When can I get Neffy in Canada?
ALK Canada has indicated that the spray could be available on the market as soon as the summer of 2026.
Is it safe for modest children?
Neffy is approved for pediatric patients, provided they weigh at least 30 kilograms (roughly 66 lbs).
Looking Ahead
The introduction of a needle-free option marks a significant milestone in allergy management. By reducing the stress and hesitation associated with injections, Neffy has the potential to save lives through faster administration of life-saving epinephrine. As it rolls out across Canada, it will likely change the standard of care for millions of people living with the risk of anaphylaxis.